Investment
Features
FeesSafety
Academy
More
Pluang+

Compare IDEXX Laboratories, Inc. (IDXX) vs Nasdaq Inc (NDAQ) Price & Performance

IDEXX Laboratories, Inc.Trade
Nasdaq IncTrade

Price performance (Past 24H)

Key statistics

IDEXX Laboratories, Inc. vs Nasdaq Inc — how do they compare? IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B), while Nasdaq Inc trades at $93.65 (market cap $51.63B). The key difference: Nasdaq Inc is the larger of the two by market cap, and Nasdaq Inc pays a 1.26% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and Nasdaq Inc for 126 Days on average.

IDXXNDAQ
Market Cap
$40.43B$51.63B
Volume
692,1642,668,175
Sector
HealthFinancials
52-Week High
$766.68$100.98
52-Week Low
$504.70$76.85
Typical Hold Time
46 Days126 Days
Enterprise Value
$41.32B$58.09B
Dividend Yield
—1.26%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

IDEXX Laboratories, Inc.

IDEXX Laboratories (IDXX) trades at $519.87, up 2.61% on the day, with a bearish technical signal from moving averages but strong fundamentals including a 25.03% net income margin and consistent earnings beats. Revenue grew to $4.3B in 2025, and the company recently acquired CoVetAI to enhance veterinary workflow intelligence, signaling strategic expansion.

The stock's outlook is supported by robust profitability and analyst consensus, but faces headwinds from technical weakness and potential market volatility. With a $665 price target implying significant upside, the primary risks include competitive pressures and execution of growth initiatives amid economic uncertainties.

Nasdaq Inc

Nasdaq Inc. (NDAQ) trades at $93.65, up 1.87% on the day, reflecting strong momentum. The stock exhibits a bullish technical signal with moving averages supporting further upside, while recent earnings beats and a 22.52% net income margin highlight robust profitability. Positive news includes the addition of Moderna to the Nasdaq-100 Index and HSBC adopting Nasdaq's Calypso platform, signaling business growth.

Outlook remains favorable with a consensus price target of $110.43, implying 18% upside. Key risks include cash flow volatility and high debt levels, but analyst sentiment is strongly bullish with 61% buy ratings. Revenue growth and AI-driven platform adoption present opportunities, though market volatility and competitive pressures warrant monitoring.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

IDXX

No sentiment data available yet.

NDAQ
51% Buy49% Sell
Avg holding period · 126 Days

Top news

Latest headlines on both assets

About IDEXX Laboratories, Inc.

Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.

Read more on IDXX →

About Nasdaq Inc

Founded in 1971, Nasdaq is primarily known for its equity exchange, but in addition to its market-services business (about 35% of sales), the company sells and distributes market data as well as offers Nasdaq-branded indexes to asset managers and investors through its information-services segment (30%). Nasdaq's corporate-services business (20%) offers listing services and related investor relations products to publicly traded companies and through the company's market technology group (15%), Nasdaq facilitates the exchange operations of other exchanges throughout the world and provides financial compliance services.

Read more on NDAQ →